EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Optimized amyloid‐β PET centiloid and cognitive cutoffs predict progression from mild cognitive impairment to Alzheimer's dementia

Rosita Shishegar, Vincent Doré, Pierrick Bourgeat, James D. Doecke, Rodrigo Cánovas, Simon M. Laws, Tenielle Porter, Michael Weiner, Colin L. Masters, Hamid R. Sohrabi, Jurgen Fripp, Paul Maruff, Victor L. Villemagne, Christopher C. Rowe

Alzheimer's & Dementia · 2026-11 · 22 (11)

DOI: 10.1002/alz.71892 ↗
AbstractBibliografische Angaben

Abstract

Abstract INTRODUCTION This study aimed to develop optimized prognostic cutoffs for amyloid‐β–positron emission tomography (Aβ‐PET) and Mini‐Mental State Examination (MMSE) that predict 3‐year progression from Clinical Dementia Rating Global (CDR‐Global) score 0.5 to 1.0 in mild cognitive impairment (MCI) participants and validate against cognitive decline/functional trajectories. METHODS We analyzed 454 CDR‐global = 0.5 Aβ‐positive (> 25 Centiloid [CL]) MCI participants from Australian Imaging Biomarkers and Lifestyle (AIBL) ( N = 99) and Alzheimer's Disease Neuroimaging Initiative (ADNI) ( N = 355), followed up to seven years. Youden index derived optimal Aβ‐PET and MMSE thresholds for 3‐year progression. Participants were stratified into four groups by combined Aβ‐PET/MMSE status. Adjusted Cox models (age, sex, education, apolipoprotein E [ APOE] ε4) assessed progression to CDR‐Global score of 1.0 Alzheimer's disease (AD) dementia (confirmed with Aβ‐PET); adjusted linear mixed models assessed CDR Sum of Boxes (CDR‐SoB) and Preclinical Alzheimer's Cognitive Composite (PACC) trajectories. RESULTS Optimal cutoffs were Aβ‐PET > 71 CL (hazard ratio [HR] = 2.67; 3‐year risk = 36.7%) and MMSE score of < 27 (HR = 2.27; 36.8%). The combined high Aβ/low MMSE group showed a 6.39‐fold risk and 47.8% 3‐year progression, with the steepest decline. DISCUSSION Prognostically optimized Aβ‐PET and MMSE cutoffs improve 3‐year risk stratification beyond common diagnostic thresholds, supporting dual‐cutoff prognostic enrichment.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →